Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Is It Time To Measure Apolipoprotein B?

Is It Time To Measure Apolipoprotein B? Editorial Is It Time To Measure Apolipoprotein B? or some time, evidence that apoproteins may pro- that is, hypertriglyceridemic patients who have an F vide information about the risk of premature coronary increased number of hepatic apo B-100 particles in disease beyond that evident in the plasma or lipoprotein plasma-appear to be at substantially greater risk for lipids has been accumulating. However, almost all of coronary disease than hypertriglyceridemic patients this has been derived from cross-sectional studies, and with normal apo B levels. Since Brown's study has therefore, appropriately, there has been reluctance to shown that hypertriglyceridemic patients who have ele- endorse the use of these measurements for routine vated apo B derive angiographic and clinical benefits clinical use. We believe the recent results of Brown et al. from pharmacologic therapy that lowers LDL particle should result in a reassessment of this view. Brown and number, surely now, the old debate on the old grounds his colleagues studied patients with documented coro- should end. nary disease and elevated apoprotein (apo) B treated The use of total apo B does not imply that all hepatic with dietary and pharmacologic regimens that were apo B particles are equally atherogenic. Even in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Arteriosclerosis Wolters Kluwer Health

Is It Time To Measure Apolipoprotein B?

Arteriosclerosis , Volume 10 (5) – Sep 1, 1990

Loading next page...
 
/lp/wolters-kluwer-health/is-it-time-to-measure-apolipoprotein-b-quest-mUgXHDsR8K
Copyright
© 1990 by American Heart Association, Inc.
ISSN
0276-5047

Abstract

Editorial Is It Time To Measure Apolipoprotein B? or some time, evidence that apoproteins may pro- that is, hypertriglyceridemic patients who have an F vide information about the risk of premature coronary increased number of hepatic apo B-100 particles in disease beyond that evident in the plasma or lipoprotein plasma-appear to be at substantially greater risk for lipids has been accumulating. However, almost all of coronary disease than hypertriglyceridemic patients this has been derived from cross-sectional studies, and with normal apo B levels. Since Brown's study has therefore, appropriately, there has been reluctance to shown that hypertriglyceridemic patients who have ele- endorse the use of these measurements for routine vated apo B derive angiographic and clinical benefits clinical use. We believe the recent results of Brown et al. from pharmacologic therapy that lowers LDL particle should result in a reassessment of this view. Brown and number, surely now, the old debate on the old grounds his colleagues studied patients with documented coro- should end. nary disease and elevated apoprotein (apo) B treated The use of total apo B does not imply that all hepatic with dietary and pharmacologic regimens that were apo B particles are equally atherogenic. Even in

Journal

ArteriosclerosisWolters Kluwer Health

Published: Sep 1, 1990

There are no references for this article.